Alioth Biotech notes that June brought the world's first solid-tumor CAR-T approval, also out of China.
Public source
Publisher name
Public post
On September 3, China's NMPA approved two homegrown long-acting RSV antibodies in a single day. Not in-licensed. Not imported. Built and owned in China. Zoom out: there…
Company
Alioth Biotech
Your Reliable Partner in Pharma Filtration Processing
- Location
- 上海, CN
- Company size
- 11–50 employees
About Alioth Biotech
Alioth Biotech (Shanghai) Co., Ltd. is a leading technology-driven company specializing in filtration and membrane separation solutions for the pharmaceutical industry. Backed by R&D teams led by internationally recognized membrane scientists in Boston and Shanghai, we develop proprietary, high-performance filtration membranes and products to optimize critical drug manufacturing processes. Operating under ISO9001 and in alignment with GMP guidelines, Alioth maintains end-to-end control of manufacturing across 15,000+ m² of multiple production facilities, supported by a CNAS-accredited validation center and process development laboratories. We are committed to delivering reliable, compliant, and innovative separation solutions for pharmaceutical partners worldwide.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
RxClarity
RxClarity reports that Autoimmune CAR-T faced a significant safety reset as Novartis and Bristol Myers Squibb paused programmes.
Legal & Regulatory
Kali Therapeutics
Kali Therapeutics received FDA clearance for its IND application for KT501, paving the way for U.S. clinical evaluation of the CD19xBCMAxCD3 tri-specific T-cell engager.
Legal & Regulatory
ViroCell Biologics
ViroCell Biologics announced the new trial using a B7H3-targeted CAR-T to treat children with relapsed and refractory extracranial solid cancers funded by Cancer Research UK, Stand Up To Cancer, and LifeArc.
Legal & Regulatory
Cellipont Bioservices
Cellipont Bioservices published a full article on the development of CAR-T therapies for autoimmune and neurological diseases, highlighting patient safety and clinical trials.
Legal & Regulatory
Ionic